In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated ...
Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the ...
The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized ...
Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.
New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first ...
Nearly 90% of patients in the MINT trial tapered prednisone to 5 mg/day or less, with no significant safety concerns seen to ...
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small ...
Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM ...
Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 ...
The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR ...
An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.
Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results